CN111110709A - Composition containing taxus chinensis extract and preparation method and application thereof - Google Patents
Composition containing taxus chinensis extract and preparation method and application thereof Download PDFInfo
- Publication number
- CN111110709A CN111110709A CN201911228160.0A CN201911228160A CN111110709A CN 111110709 A CN111110709 A CN 111110709A CN 201911228160 A CN201911228160 A CN 201911228160A CN 111110709 A CN111110709 A CN 111110709A
- Authority
- CN
- China
- Prior art keywords
- taxus chinensis
- extract
- composition containing
- chinensis extract
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 74
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000000605 extraction Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 239000000853 adhesive Substances 0.000 claims abstract description 25
- 230000001070 adhesive effect Effects 0.000 claims abstract description 25
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 102000004243 Tubulin Human genes 0.000 claims abstract description 20
- 108090000704 Tubulin Proteins 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- KAIPKTYOBMEXRR-UHFFFAOYSA-N 1-butyl-3-methyl-2h-imidazole Chemical compound CCCCN1CN(C)C=C1 KAIPKTYOBMEXRR-UHFFFAOYSA-N 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000001694 spray drying Methods 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000007939 sustained release tablet Substances 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000004203 carnauba wax Substances 0.000 claims description 3
- 235000013869 carnauba wax Nutrition 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 241001116500 Taxus Species 0.000 abstract description 18
- 230000001093 anti-cancer Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 229930012538 Paclitaxel Natural products 0.000 abstract description 4
- 229960001592 paclitaxel Drugs 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 229930004069 diterpene Natural products 0.000 abstract description 2
- 125000000567 diterpene group Chemical group 0.000 abstract description 2
- 229930013686 lignan Natural products 0.000 abstract description 2
- 235000009408 lignans Nutrition 0.000 abstract description 2
- 150000005692 lignans Chemical class 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 26
- 239000000843 powder Substances 0.000 description 19
- 230000035755 proliferation Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a composition containing a taxus extract, a preparation method and an application thereof, wherein the composition comprises the following components in parts by mass: 1-80 parts of a taxus chinensis extract and 1-20 parts of a tubulin adhesive. The taxus extract not only contains taxol, but also comprises more than 30 anticancer substances such as lignans, diterpenes and the like and more than 100 other natural components, and finally realizes the anticancer function without side effect by blending the natural components. And combining with microscopic protein adhesive to make the yew extract act on cancer cells.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparation, and particularly relates to a composition containing a taxus chinensis extract, and a preparation method and application thereof.
Background
Taxus chinensis belongs to shallow root plants, has unobvious main roots and developed lateral roots, is a natural rare anti-cancer plant which is known to be endangered to extinct in the world, is an ancient wiggle tree species which is left over by the fourth glacier, and has a history of 250 ten thousand years on the earth. Because the growth rate of the taxus chinensis is slow and the regeneration capability is poor under natural conditions, a large-scale taxus chinensis raw material forest base has not been formed in the world for a long time.
The anticancer function of natural components contained in the taxus chinensis is scientifically proved to comprise:
(1) selective anticancer function without damaging normal cells and only aiming and eliminating cancer cells;
(2) inducing cancer cell apoptosis (apoptosis) by directly attacking cancer cells;
(3) the unique immunopotentiation (Fas antigen expression) that causes macrophages to directly engulf live cancer cells.
Any of the above effects is of great significance, especially the function of "targeting and eliminating only cancer cells" mentioned in point (1). This selective anti-cancer function is a very difficult feature that existing anti-cancer drugs should possess.
Anticancer drugs tend to kill both cancer cells and normal cells. Therefore, anticancer drugs easily cause serious side effects and cause many patients to abandon the treatment.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention provides a composition containing a taxus extract, which is used for partially solving the problem that the existing approved anticancer drugs including paclitaxel and the like have side effects. And combining with microscopic protein adhesive to make the yew extract act on cancer cells.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
a composition containing a taxus chinensis extract comprises the following components in parts by mass:
1-80 parts of a taxus chinensis extract and 1-20 parts of a tubulin adhesive.
Preferably, the composition containing the taxus chinensis extract comprises the following components in parts by mass:
10-60 parts of a taxus chinensis extract and 10-15 parts of a tubulin adhesive.
Preferably, the taxus chinensis extract is a solid, and more preferably is prepared by spray drying of an aqueous extract or an organic solvent extract of one or more of branches, leaves and seeds of the taxus chinensis.
Preferably, the organic solvent comprises one or a combination of more than one of ethanol, methanol and 1-butyl-3-methylimidazole trichloro-ferric bromide, more preferably, the organic solvent consists of ethanol and 1-butyl-3-methylimidazole trichloro-ferric bromide, and more preferably, the volume of the 1-butyl-3-methylimidazole trichloro-ferric bromide is 5-8% of that of the ethanol.
Preferably, the composition containing the taxus chinensis extract further comprises a pharmaceutical adjuvant, wherein the pharmaceutical adjuvant comprises one or a combination of several of an excipient, an adhesive, a lubricant and a disintegrating agent.
Preferably, the filler comprises one or more of lactose, sucrose, starch, microcrystalline cellulose, sorbitol and cellulose.
Preferably, the binder comprises one or more of gelatin, hydroxypropyl methylcellulose, polyvinylpyrrolidone, starch and maltodextrin.
Preferably, the disintegrating agent comprises one or more of microcrystalline cellulose, sodium carboxymethyl starch, sodium carboxymethyl cellulose and polyvinylpyrrolidone.
Preferably, the lubricant comprises magnesium stearate and/or a polymeric matrix material;
more preferably, the polymer skeleton material comprises one or more of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, ethyl cellulose, carnauba wax, hydrogenated vegetable oil and acrylic resin.
Preferably, the dosage forms of the composition containing the taxus chinensis extract comprise tablets, dispersible granules, capsules, sustained-release tablets and sustained-release pellets.
The preparation method of the composition containing the taxus chinensis extract is characterized by comprising the following steps of:
mixing the taxus chinensis extract, the tubulin adhesive and optional pharmaceutical excipients to prepare the preparation.
An application of the composition containing the taxus chinensis extract in preparing a medicine for treating human or animal cancers.
Preferably, the cancer includes cervical cancer, colorectal cancer, brain cancer, ovarian cancer, lung cancer, leukemia and liver cancer.
A health food comprises the composition containing Taxus chinensis extract.
Compared with the prior art, the invention has the beneficial effects that:
(1) the composition containing the taxus chinensis extract provided by the application is combined with the microscopic protein, so that the comprehensive effect of the taxus chinensis extract is improved.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following detailed description, but those skilled in the art will understand that the following described examples are some, not all, of the examples of the present invention, and are only used for illustrating the present invention, and should not be construed as limiting the scope of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The invention provides a composition containing a taxus chinensis extract, which comprises the following components in parts by mass:
1-80 parts of a taxus chinensis extract and 1-20 parts of a tubulin adhesive.
The taxus extract not only contains taxol, but also comprises more than 30 anticancer substances such as lignans, diterpenes and the like and more than 100 other natural components, and finally realizes the anticancer function without side effect by blending the natural components. And the micro protein adhesive is combined, so that the taxus chinensis extract acts on cancer cells, and the transfer performance of the medicine is improved.
In some preferred embodiments provided by the present invention, the ratio of the taxus extract to the tubulin adhesive is further defined, and the composition containing the taxus extract comprises the following components in parts by mass:
10-60 parts of a taxus chinensis extract and 10-15 parts of a tubulin adhesive.
In some preferred embodiments of the present invention, the taxus chinensis extract is a solid, and more preferably is prepared by spray drying an aqueous extract or an organic solvent extract comprising one or more of branches, leaves and seeds of taxus chinensis.
In some preferred embodiments provided by the present invention, the organic solvent includes one or a combination of several of ethanol, methanol and 1-butyl-3-methylimidazole trichloro-ferric bromide, more preferably, the organic solvent is composed of ethanol and 1-butyl-3-methylimidazole trichloro-ferric bromide, more preferably, the volume of the 1-butyl-3-methylimidazole trichloro-ferric bromide is 5% to 8% of that of the ethanol, and such an extract can retain not only paclitaxel in taxus chinensis but also other effective components, thereby reducing side effects of the drug.
In some preferred embodiments provided by the present invention, the composition containing the taxus chinensis extract further comprises a pharmaceutical adjuvant, and the pharmaceutical adjuvant comprises one or a combination of several of an excipient, a binder, a lubricant and a disintegrant.
The pharmaceutic adjuvant comprises the following excipients: filling agent: lactose, sucrose, starch, microcrystalline cellulose, sorbitol, cellulose. Adhesive: gelatin, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, starch and dextrin. Disintegrating agent: microcrystalline cellulose, sodium carboxymethyl starch, sodium carboxymethyl cellulose and polyvinylpyrrolidone. Lubricant: magnesium stearate; high molecular skeleton materials such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, ethyl cellulose, carnauba wax, hydrogenated vegetable oils, and acrylic resins. The composition was prepared as follows: the compounds of the present invention are combined with pharmaceutically acceptable solid or liquid carriers and optionally with pharmaceutically acceptable adjuvants and excipients using standard and conventional techniques to prepare microparticles or microspheres. Solid dosage forms include tablets, dispersible granules, capsules, sustained release tablets, sustained release pellets and the like. A solid carrier can be at least one substance that can act as a diluent, flavoring agent, solubilizing agent, lubricant, suspending agent, binder, disintegrant, and encapsulating agent. Inert solid carriers include magnesium phosphate, magnesium stearate, powdered sugar, lactose, pectin, propylene glycol, polysorbate 80, dextrin, starch, gelatin, cellulosic materials such as methyl cellulose, microcrystalline cellulose, low melting paraffin, polyethylene glycol, mannitol, cocoa butter, and the like. Liquid dosage forms include solvents, suspensions such as injections, powders, and the like.
The preparation method of the composition containing the taxus chinensis extract is characterized by comprising the following steps of:
mixing the taxus chinensis extract, the tubulin adhesive and optional pharmaceutical excipients to prepare the preparation.
The invention provides application of a composition containing a taxus chinensis extract in preparing a medicine for treating human or animal cancers.
In some preferred embodiments provided herein, the cancer includes cervical cancer, colorectal cancer, brain cancer, ovarian cancer, lung cancer, leukemia, and liver cancer.
The health food provided by the invention comprises the composition containing the taxus chinensis extract.
Example 1
Preparing 1 part of taxus extract powder, 1 part of tubulin adhesive and a proper amount of auxiliary materials into tablets.
The Taxus chinensis extract powder is obtained by spray drying water extract of Taxus chinensis.
Example 2
80 parts of taxus extract powder, 20 parts of tubulin adhesive and a proper amount of auxiliary materials are prepared into tablets.
The Taxus chinensis extract powder is obtained by spray drying ethanol extract of Taxus chinensis.
Example 3
70 parts of taxus extract powder, 18 parts of tubulin adhesive and a proper amount of auxiliary materials are prepared into tablets.
The Taxus chinensis extract powder is obtained by spray drying ethanol extract of Taxus chinensis.
Example 4
The capsule is prepared by 10 parts of taxus extract powder, 10 parts of tubulin adhesive and a proper amount of auxiliary materials.
The Taxus chinensis extract powder is obtained by spray drying ethanol extract of Taxus chinensis.
Example 5
60 parts of taxus extract powder, 15 parts of tubulin adhesive and a proper amount of auxiliary materials are prepared into capsules.
The Taxus chinensis extract powder is obtained by spray drying ethanol extract of Taxus chinensis.
Example 6
The capsule is prepared by 20 parts of taxus extract powder, 10 parts of tubulin adhesive and a proper amount of auxiliary materials.
The Taxus chinensis extract powder is obtained by spray drying ethanol extract of Taxus chinensis.
Example 7
The sustained-release tablet is prepared by 50 parts of taxus extract powder, 12 parts of tubulin adhesive and a proper amount of auxiliary materials.
The Taxus chinensis extract powder is obtained by spray drying ethanol extract of Taxus chinensis.
Example 8
60 parts of taxus extract powder, 10 parts of tubulin adhesive and a proper amount of auxiliary materials are prepared into a sustained-release capsule.
Wherein the Taxus chinensis extract powder is obtained by extracting Taxus chinensis with an extracting solution consisting of ethanol and 1-butyl-3-methylimidazole trichloro-ferric bromide and then spray drying, and the volume of the 1-butyl-3-methylimidazole trichloro-ferric bromide is 5-8% of that of the ethanol.
The slow release capsule is prepared by 60 parts of taxus chinensis extract powder and a proper amount of auxiliary materials.
Wherein the Taxus chinensis extract powder is obtained by extracting Taxus chinensis with an extracting solution consisting of ethanol and 1-butyl-3-methylimidazole trichloro-ferric bromide and then spray drying, and the volume of the 1-butyl-3-methylimidazole trichloro-ferric bromide is 5-8% of that of the ethanol.
Experimental example inhibition of proliferation of cancer cells and Normal cells
The proliferation inhibitory effects of the sustained-release capsules obtained in example 8 and comparative example were tested on cancer cells and normal cells. The results are shown in Table 1.
TABLE 1 inhibition of proliferation of cancer cells and normal cells (IC 50 value)
| Cancer cells | Example 8 (μ g/ml) | COMPARATIVE EXAMPLE (μ g/ml) |
| Cervical cancer | 0.0230 | 0.0321 |
| Large intestine cancer | 0.0300 | 0.0412 |
| Brain cancer | 0.0515 | 0.0656 |
| Ovarian cancer | 0.0575 | 0.0662 |
| Lung cancer | 0.0660 | 0.0821 |
| Leukemia (leukemia) | 0.1725 | 0.2015 |
| Liver cancer | 1.0910 | 1.1271 |
| Normal fibroblast | No proliferation inhibitory effect | No proliferation inhibitory effect |
| Normal lung cell | No proliferation inhibitory effect | No proliferation inhibitory effect |
The experimental results show that the taxus chinensis composition provided by the application has a strong proliferation inhibition effect on cervical cancer, colorectal cancer, brain cancer, ovarian cancer, lung cancer, leukemia, liver cancer and the like. Cancer cells that undergo apoptosis as a result of the progression of yew break into fragments and die in the near future. The fragmented cancer cells will then be engulfed by macrophages. This is the unique immune activation function of the yew. When cancer cells encounter the taxus chinensis extract, macrophages can swallow not only carcasses of the cancer cells, but also live cancer cells directly.
On the other hand, division and proliferation of normal fibroblasts and normal lung cells are still normally performed. That is, Taxus chinensis does not damage normal cells at all, and only inhibits division and proliferation of cancer cells. The selective anticancer function which only attacks cancer cells and has no influence on normal cells is the primary characteristic of the anticancer function of the taxus chinensis and is the most important factor considering the anticancer function without side effect.
In addition, the addition of tubulin binder helps to increase the inhibitory effect of the Taxus chinensis extract on cancer cells.
While particular embodiments of the present invention have been illustrated and described, it will be appreciated that the above embodiments are merely illustrative of the technical solution of the present invention and are not restrictive; those of ordinary skill in the art will understand that: modifications may be made to the above-described embodiments, or equivalents may be substituted for some or all of the features thereof without departing from the spirit and scope of the present invention; the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention; it is therefore intended to cover in the appended claims all such alternatives and modifications that are within the scope of the invention.
Claims (10)
1. The composition containing the taxus chinensis extract is characterized by comprising the following components in parts by mass:
1-80 parts of a taxus chinensis extract and 1-20 parts of a tubulin adhesive.
2. The composition containing the taxus chinensis extract as claimed in claim 1, which is characterized by comprising the following components in parts by mass:
10-60 parts of a taxus chinensis extract and 10-15 parts of a tubulin adhesive.
3. The composition containing the taxus chinensis extract as claimed in claim 1 or 2, wherein the taxus chinensis extract is solid, preferably prepared by spray drying of an aqueous extract or an organic solvent extract comprising one or more of branches, leaves and seeds of taxus chinensis.
4. The composition containing taxus chinensis extract as claimed in claim 3, wherein the organic solvent comprises one or more of ethanol, methanol and 1-butyl-3-methylimidazole trichloro-ferric bromide, preferably the organic solvent consists of ethanol and 1-butyl-3-methylimidazole trichloro-ferric bromide, more preferably the 1-butyl-3-methylimidazole trichloro-ferric bromide is 5% to 8% of the volume of the ethanol.
5. The composition containing the taxus chinensis extract as claimed in claim 1 or 2, further comprising a pharmaceutic adjuvant, wherein the pharmaceutic adjuvant comprises one or a combination of excipients, binders, lubricants and disintegrants;
preferably, the filler comprises one or more of lactose, sucrose, starch, microcrystalline cellulose, sorbitol and cellulose;
preferably, the adhesive comprises one or a combination of several of gelatin, hydroxypropyl methylcellulose, polyvinylpyrrolidone, starch and maltodextrin;
preferably, the disintegrating agent comprises one or a combination of more of microcrystalline cellulose, sodium carboxymethyl starch, sodium carboxymethyl cellulose and polyvinylpyrrolidone;
preferably, the lubricant comprises magnesium stearate and/or a polymeric matrix material;
more preferably, the polymer skeleton material comprises one or more of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, ethyl cellulose, carnauba wax, hydrogenated vegetable oil and acrylic resin.
6. The composition containing the taxus chinensis extract as claimed in claim 1 or 2, wherein the dosage forms of the composition containing the taxus chinensis extract comprise tablets, dispersible granules, capsules, sustained-release tablets and sustained-release pellets.
7. The method for preparing a composition containing an extract of taxus chinensis as claimed in any one of claims 1 to 6, comprising the steps of:
mixing the taxus chinensis extract, the tubulin adhesive and optional pharmaceutical excipients to prepare the preparation.
8. Use of a composition comprising an extract of Taxus chinensis as claimed in any one of claims 1-6 in the manufacture of a medicament for the treatment of human or animal cancer.
9. The use of claim 8, wherein the cancer comprises cervical cancer, colorectal cancer, brain cancer, ovarian cancer, lung cancer, leukemia and liver cancer.
10. A health food comprising the composition containing Taxus chinensis extract as claimed in any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911228160.0A CN111110709A (en) | 2019-12-04 | 2019-12-04 | Composition containing taxus chinensis extract and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911228160.0A CN111110709A (en) | 2019-12-04 | 2019-12-04 | Composition containing taxus chinensis extract and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111110709A true CN111110709A (en) | 2020-05-08 |
Family
ID=70497330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911228160.0A Pending CN111110709A (en) | 2019-12-04 | 2019-12-04 | Composition containing taxus chinensis extract and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111110709A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1594247A (en) * | 2004-06-23 | 2005-03-16 | 黑龙江省紫杉科技股份有限公司 | Yew genus plant extract and its extraction method and application |
| CN103446194A (en) * | 2012-05-28 | 2013-12-18 | 浙江百年红豆杉生物科技有限公司 | Anti-cancer oral medicine prepared from Chinese yew extract |
| CN106749114A (en) * | 2017-02-24 | 2017-05-31 | 中国农业科学院麻类研究所 | A kind of method that taxol is extracted from Chinese yew |
-
2019
- 2019-12-04 CN CN201911228160.0A patent/CN111110709A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1594247A (en) * | 2004-06-23 | 2005-03-16 | 黑龙江省紫杉科技股份有限公司 | Yew genus plant extract and its extraction method and application |
| CN103446194A (en) * | 2012-05-28 | 2013-12-18 | 浙江百年红豆杉生物科技有限公司 | Anti-cancer oral medicine prepared from Chinese yew extract |
| CN106749114A (en) * | 2017-02-24 | 2017-05-31 | 中国农业科学院麻类研究所 | A kind of method that taxol is extracted from Chinese yew |
Non-Patent Citations (1)
| Title |
|---|
| 白军 等: "紫花牡荆素药理作用的研究进展", 中国新药杂志, vol. 19, no. 21, pages 1954 - 1957 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5300195B2 (en) | Composition of botanical extract for cancer treatment | |
| Valdiani et al. | Nain-e Havandi Andrographis paniculata present yesterday, absent today: a plenary review on underutilized herb of Iran’s pharmaceutical plants | |
| Willcox | Improved traditional phytomedicines in current use for the clinical treatment of malaria | |
| TWI527582B (en) | Tocotrienol compositions | |
| Baliga | Review of the phytochemical, pharmacological and toxicological properties of Alstonia scholaris Linn. R. Br (Saptaparna) | |
| AU2011323155B2 (en) | Combination therapy for prostate cancer using botanical compositions and bicalutamide | |
| CN105769891A (en) | Low-polarity rare ginsenoside mixture and application thereof | |
| Kumar et al. | Conservation status, anticancer compounds and pharmacological aspects of royle: a review Podophyllum hexandrum | |
| JP6837960B2 (en) | Compositions containing melatonin and flavonoids for use in the treatment of chemotherapy-resistant tumors | |
| DK2952201T3 (en) | Compositions of Alpinia galanga or Alpinia conchigera with high content of 1´S-1´-acetoxychavicol acetate suitable for pharmaceutical use | |
| WO2018217237A1 (en) | Combination therapy for cancer using botanical compositions and enzalutamide | |
| CA2951110A1 (en) | Combination therapy for prostate cancer using botanical compositions and docetaxel | |
| CN111110709A (en) | Composition containing taxus chinensis extract and preparation method and application thereof | |
| CN101773532B (en) | Carpesium abrotanoides total terpene lactones extract | |
| CN106176787B (en) | The application and drug of forsythin, Fructus Forsythiae glycoside derivates, forsythin and phillygenol composition in preparation anticancer or anti-tumor drug | |
| CN104524139B (en) | Allium wallichii extract and application thereof | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| Tejasari et al. | Anticancer activity of novel soursop leaves active compound (SF-1603) through apoptotic induction in liver cancer | |
| CN107530386A (en) | For treating the composition of chemoresistant tumour | |
| CN104771463B (en) | New application of the european bird cherry extract in alcoholic liver injury protection medicine and health products are prepared | |
| CN103656646A (en) | Anti-tumor drug composition and application thereof | |
| JP2005052155A (en) | Food composition containing taxus yunnanensis and tecoma | |
| WO2009074065A1 (en) | Use of daphne primeverose genkwanine and daphne plants | |
| Balamurugan et al. | Cytotoxic activity of leaves extract of pomegranate (Punica granatum L.) | |
| KAUR et al. | Aegle marmelos: Review of traditional uses, Phyotochemistry, Pharmacological activities. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |